Answers are grounded in this paper and cite their sources.
AIMS: In individuals with obesity, glomerular hyperfiltration compensates for the heightened metabolic demands of increased body weight. This study investigated whether extended-release naltrexone/bupropion (NB) was associated with changes consistent with hyperfiltration reversal in adults with overweight or obesity. MATERIALS AND METHODS: Post hoc, exploratory analyses were conducted in both per-protocol subjects completing 56 weeks of treatment and the intention-to-treat population in Phase III studies (COR-I and -II, COR-BMOD). A mixed-effects model investigated if NB was associated with changes in renal function consistent with presumed hyperfiltration reversal. Obesity-related hyperfiltration was defined as creatinine clearance (CrCl) > 120 mL/min and estimated using the Salazar-Corcoran equation. At 56 weeks, mean weight loss was 9.0 kg in the NB group and 2.8 kg in the placebo group (p < 0.0001). During that period, adjusted mean CrCl decreased by 8.4 mL/min in the NB group (from 125.1 to 116.7 mL/min), compared to a marginal increase of 0.1 mL/min in the placebo group (from 124.0 to 124.1 mL/min; between-group difference in change of -8.5 mL/min; 95% CI: -9.7 to -7.4) in favour of NB. The adjusted percentage of subjects with CrCl values consistent with presumed obesity-related hyperfiltration decreased significantly from 49.9% to 14.1% in the NB group and changed from 41.1% to 43.4% in the placebo group, corresponding to an absolute between-group difference in change of -38.2 percentage points (95% CI: -55.3 to -21.0). The results were consistent in the ITT population, with adjusted rates decreasing from 35.8% to 4.0% in the NB group and from 36.7% to 33.7% in the placebo group, corresponding to an absolute between-group difference in change of -29.7 percentage points (95% CI: -43.1 to -16.2). CONCLUSIONS: Over 56 weeks, NB was associated with a significant reduction in the proportion of subjects with presumed renal hyperfiltration compared to placebo. TRIAL REGISTRATION: COR-I: NCT00532779; COR-II: NCT00567255; COR-BMOD: NCT00456521.
No takes yet. Share an insight, caveat, or question.
Tsoukas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: